Vitaly Margulis1,2, Maneka Puligandla3, Edouard J Trabulsi4, Elizabeth R Plimack5, Elizabeth R Kessler6, Surena F Matin7, Guilherme Godoy8, Ajjai Alva9, Noah M Hahn10, Michael A Carducci10, Jean Hoffman-Censits11,10. 1. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. 2. Institute of Urology and Reproductive Health, Sechenov University, Moscow, Russia. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. 5. Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 6. Division of Medical Oncology, Department of Internal Medicine, University of Colorado, Aurora, Colorado. 7. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Urology, Baylor College of Medicine, Houston, Texas. 9. Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan (AA), Ann Arbor, Michigan. 10. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, Maryland. 11. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
PURPOSE: Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma. MATERIALS AND METHODS: Patients with high grade upper tract urothelial carcinoma in whom nephroureterectomy was planned were assigned to 4 neoadjuvant chemotherapy cycles of accelerated methotrexate, vinblastine, doxorubicin and cisplatin in those with baseline creatinine clearance greater than 50 ml per minute or gemcitabine and carboplatin in those with creatinine clearance 30 to 50 ml per minute or less. The study primary end point was a pathological complete response (ypT0N0). The accrual goal was 30 patients per arm. An 18% pathological complete response was considered worth further study while a 4% pathological complete response would not have justified pursuing this regimen. With 28 eligible patients per arm success was defined as 3 or more pathological complete responses (10.7%) in a given arm. Secondary end points included safety, renal function and oncologic outcomes. RESULTS: A total of 30 patients enrolled in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm from 2015 to 2017. Six patients enrolled in the gemcitabine and carboplatin arm, which closed due to poor accrual. Of the 29 patients eligible for accelerated methotrexate, vinblastine, doxorubicin and cisplatin, including 23 men and 6 women with a median age of 65 years (range 40 to 84), 80% completed all planned treatments, 3 (10.3%) achieved ypT0N0 and 1 achieved ypT0Nx for a pathological complete response in 13.8% (90% CI 4.9-28.8). In 1 patient receiving accelerated methotrexate, vinblastine, doxorubicin and cisplatin nephroureterectomy was deferred due to grade 4 sepsis. The grade 3-4 toxicity rate was 23% in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm with no grade 5 event. CONCLUSIONS: Accelerated methotrexate, vinblastine, doxorubicin and cisplatin neoadjuvant chemotherapy in patients with high grade upper tract urothelial carcinoma and creatinine clearance greater than 50 ml per minute was safe and demonstrated predefined activity with a 14% pathological complete response rate. Final pathological stage ypT1 or less in more than 60% of patients is encouraging. Together the results of this prospective trial support the use of neoadjuvant chemotherapy in eligible patients with high grade upper tract urothelial carcinoma.
PURPOSE: Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma. MATERIALS AND METHODS:Patients with high grade upper tract urothelial carcinoma in whom nephroureterectomy was planned were assigned to 4 neoadjuvant chemotherapy cycles of accelerated methotrexate, vinblastine, doxorubicin and cisplatin in those with baseline creatinine clearance greater than 50 ml per minute or gemcitabine and carboplatin in those with creatinine clearance 30 to 50 ml per minute or less. The study primary end point was a pathological complete response (ypT0N0). The accrual goal was 30 patients per arm. An 18% pathological complete response was considered worth further study while a 4% pathological complete response would not have justified pursuing this regimen. With 28 eligible patients per arm success was defined as 3 or more pathological complete responses (10.7%) in a given arm. Secondary end points included safety, renal function and oncologic outcomes. RESULTS: A total of 30 patients enrolled in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm from 2015 to 2017. Six patients enrolled in the gemcitabine and carboplatin arm, which closed due to poor accrual. Of the 29 patients eligible for accelerated methotrexate, vinblastine, doxorubicin and cisplatin, including 23 men and 6 women with a median age of 65 years (range 40 to 84), 80% completed all planned treatments, 3 (10.3%) achieved ypT0N0 and 1 achieved ypT0Nx for a pathological complete response in 13.8% (90% CI 4.9-28.8). In 1 patient receiving accelerated methotrexate, vinblastine, doxorubicin and cisplatin nephroureterectomy was deferred due to grade 4 sepsis. The grade 3-4 toxicity rate was 23% in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm with no grade 5 event. CONCLUSIONS: Accelerated methotrexate, vinblastine, doxorubicin and cisplatin neoadjuvant chemotherapy in patients with high grade upper tract urothelial carcinoma and creatinine clearance greater than 50 ml per minute was safe and demonstrated predefined activity with a 14% pathological complete response rate. Final pathological stage ypT1 or less in more than 60% of patients is encouraging. Together the results of this prospective trial support the use of neoadjuvant chemotherapy in eligible patients with high grade upper tract urothelial carcinoma.
Entities:
Keywords:
carcinoma; drug therapy; nephroureterectomy; urinary tract; urothelium
Authors: Jeffrey J Leow; William Martin-Doyle; André P Fay; Toni K Choueiri; Steven L Chang; Joaquim Bellmunt Journal: Eur Urol Date: 2014-03-16 Impact factor: 20.096
Authors: Atiqullah Aziz; Jakub Dobruch; Kees Hendricksen; Luis A Kluth; Andrea Necchi; Aidan Noon; Michael Rink; Florian Roghmann; Roland Seiler; Paolo Gontero; Wassim Kassouf; Shahrokh F Shariat; Evanguelos Xylinas Journal: World J Urol Date: 2017-01-10 Impact factor: 4.226
Authors: Andrea Necchi; Salvatore Lo Vullo; Luigi Mariani; Marco Moschini; Kees Hendricksen; Michael Rink; Roman Sosnowski; Jakub Dobruch; Jay D Raman; Christopher G Wood; Vitaly Margulis; Morgan Roupret; Alberto Briganti; Francesco Montorsi; Evanguelos Xylinas; Shahrokh F Shariat Journal: BJU Int Date: 2017-10-12 Impact factor: 5.588
Authors: Matthew D Galsky; Kristian D Stensland; Erin Moshier; John P Sfakianos; Russell B McBride; Che-Kai Tsao; Martin Casey; Paolo Boffetta; William K Oh; Madhu Mazumdar; Juan P Wisnivesky Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Cora N Sternberg; Iwona Skoneczna; J Martijn Kerst; Peter Albers; Sophie D Fossa; Mads Agerbaek; Herlinde Dumez; Maria de Santis; Christine Théodore; Michael G Leahy; John D Chester; Antony Verbaeys; Gedske Daugaard; Lori Wood; J Alfred Witjes; Ronald de Wit; Lionel Geoffrois; Lisa Sengelov; George Thalmann; Danielle Charpentier; Frédéric Rolland; Laurent Mignot; Santhanam Sundar; Paul Symonds; John Graham; Florence Joly; Sandrine Marreaud; Laurence Collette; Richard Sylvester Journal: Lancet Oncol Date: 2014-12-11 Impact factor: 41.316
Authors: Nirmish Singla; Ryan Hutchinson; Colleen Menegaz; Ahmed Q Haddad; Lai Jiang; Arthur I Sagalowsky; Jeffrey A Cadeddu; Yair Lotan; Vitaly Margulis Journal: Urology Date: 2016-07-18 Impact factor: 2.649
Authors: Dan Leibovici; Wassim Kassouf; Louis L Pisters; Curtis A Pettaway; Xifeng Wu; Colin P Dinney; H Barton Grossman Journal: Urology Date: 2007-09 Impact factor: 2.649
Authors: Toni K Choueiri; Susanna Jacobus; Joaquim Bellmunt; Angela Qu; Leonard J Appleman; Christopher Tretter; Glenn J Bubley; Edward C Stack; Sabina Signoretti; Meghara Walsh; Graeme Steele; Michelle Hirsch; Christopher J Sweeney; Mary-Ellen Taplin; Adam S Kibel; Katherine M Krajewski; Philip W Kantoff; Robert W Ross; Jonathan E Rosenberg Journal: J Clin Oncol Date: 2014-05-12 Impact factor: 44.544
Authors: Matthew I Milowsky; R Bryan Rumble; Christopher M Booth; Timothy Gilligan; Libni J Eapen; Ralph J Hauke; Pat Boumansour; Cheryl T Lee Journal: J Clin Oncol Date: 2016-03-21 Impact factor: 44.544
Authors: Omar Alhalabi; Matthew T Campbell; Lianchun Xiao; Ana C Adriazola; Nathaniel R Wilson; Arlene O Siefker-Radtke; Paul G Corn; Amado Zurita; Eric Jonasch; Jianjun Gao; Mehrad Adibi; Ashish M Kamat; Neema Navai; Louis L Pisters; Colin Dinney; Surena F Matin; Amishi Y Shah Journal: BJUI Compass Date: 2021-10-11